Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their DecisionJames R. Wright, Mark N. Levine, Timothy J. Whelan et al.|Journal of Clinical Oncology|2004Cited by 138
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Patrick M. Forde et al.|npj Precision Oncology|2022Cited by 42